Federal Register / Vol. 72, No. 212 / Friday, November 2, 2007 / Notices 62223 

necessary to implement an agreement 

with one or more NAFTA country on 

such a modification. See section 202(q) 

of the NAFTA Implementation Act. 

On October 29, 2007, the Chairman of 

CITA received a request from Monterey 

Mills, alleging that certain acrylic staple 

fibers, not carded, combed or otherwise 

processed for spinning, classified under 

subheading 5503.30 of the Harmonized 

Tariff Schedule of the United States 

(HTSUS), cannot be supplied by the 

domestic industry in commercial 

quantities in a timely manner and 

requesting that CITA consider whether 

the North American Free Trade 

Agreement (NAFTA) rule of origin for 

knit pile fabrics, classified under 

HTSUS subheading 6001.10, should be 

modified to allow the use of non-North 

American acrylic staple fiber. 

CITA is soliciting public comments 

regarding this request, particularly with 

respect to whether the acrylic staple 

fiber described above can be supplied 

by the domestic industry in commercial 

quantities in a timely manner. 

Comments must be received no later 

than December 3, 2007. Interested 

persons are invited to submit six copies 

of such comments or information to the 

Chairman, Committee for the 

Implementation of Textile Agreements, 

Room 3100, U.S. Department of 

Commerce, 14th and Constitution 

Avenue, N.W., Washington, DC 20230. 

If a comment alleges that these acrylic 

staple fibers can be supplied by the 

domestic industry in commercial 

quantities in a timely manner, CITA will 

closely review any supporting 

documentation, such as a signed 

statement by a manufacturer stating that 

it produces fiber that is the subject of 

the request, including the quantities that 

can be supplied and the time necessary 

to fill an order, as well as any relevant 

information regarding past production. 

CITA will protect any business 

confidential information that is marked 

business confidential from disclosure to 

the full extent permitted by law. CITA 

will make available to the public nonconfidential versions of the request and 

non-confidential versions of any public 

comments received with respect to a 

request in room 3100 in the Herbert 

Hoover Building, 14th and Constitution 

Avenue, N.W., Washington, DC 20230. 

Persons submitting comments on a 

request are encouraged to include a nonconfidential version and a nonconfidential summary. 

R. Matthew Priest, 

Chairman, Committee for the Implementation 

of Textile Agreements. 

[FR Doc. E7–21627 Filed 11–1–07; 8:45 am] 

BILLING CODE 3510–DS 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

Defense Health Board (DHB) Meeting 

AGENCY: Department of Defense. 

ACTION: Notice of meeting. 

SUMMARY: Pursuant to the Federal 

Advisory Committee Act of 1972 (5 

U.S.C. Appendix as amended), the 

Sunshine in the Government Act of 

1976 (5 U.S.C. 552b, as amended), and 

41 CFR 102–3.150, and in accordance 

with section 10(a)(2) of Public Law, the 

following meeting is announced: 

Name of Committee: Defense Health 

Board (DHB). 

Dates: December 11 and 12, 2007. 

Times: December 11, 2007. 

8 a.m.–12:15 p.m. (Open Session). 

1:30 p.m.–4:15 p.m. (Open Session). 

December 12, 2007. 

8:30 a.m.–12 p.m. (Open Session). 

Place of Meeting: Sheraton Crystal 

City, 1800 Jefferson Davis Highway, 

Arlington, Virginia 22202. 

Purpose of the Meeting: The purpose 

of the meeting is to address and 

deliberate pending and new Board 

issues and provide briefings for Board 

members on topics related to ongoing 

Board business. 

Agenda: The Board will deliberate the 

findings and recommendations of the 

Task Force on the Future of Military 

Health Care and receive an update on 

the Department’s efforts to reengineer 

the Disability Evaluation Program. The 

Board will receive reports from the 

Psychological Health and Traumatic 

Brain Injury External Advisory 

Subcommittees. The Board will also 

deliberate recommendations regarding 

Emergency Blood Transfusion Safety 

and discuss DoD’s convalescent plasma 

treatment guidelines development. 

Pandemic influenza preparedness and 

Chlamydia infection control will also be 

discussed. 

On December 12, 2007, the board will 

hold a short preparatory session before 

the beginning of the open meeting and 

an administrative session after the open 

meeting is adjourned. The preparatory 

and administrative sessions are closed 

to the public. 

Pursuant to 5 U.S.C. 552b, as 

amended, and 41 CFR 102–3.140 

through 102–3.165 and subject 

availability of space, the Defense Health 

Board meeting from 8 a.m. to 4:15 p.m. 

on December 11, 2007 and from 8:30 

a.m. to 12 p.m. on December 12, 2007 

is open to the public. Any member of 

the public wishing to provide input to 

the Defense Health Board should submit 

a written statement in accordance with 

41 CFR 102–3.140(C) and section 

10(a)(3) of the Federal Advisory 

Committee Act, and the procedures 

described in this notice. Written 

statement should be not longer than two 

type-written pages and must address the 

following detail: The issue, discussion, 

and a recommended course of action. 

Supporting documentation may also be 

included as needed to establish the 

appropriate historical context and to 

provide any necessary background 

information. 

Individuls desiring to submit a 

written statement may do so through the 

Board’s Designated Federal Officer at 

the address detailed below at any point. 

However, if the written statement is not 

received at least 10 calendar days prior 

to the meeting, which is subject to this 

notice, then it may not be provided to 

or considered by the Defense Health 

Board until the next open meeting. 

The Designated Federal Officer will 

review all timely submissions with the 

Defense Health Board Chairperson, and 

ensure they are provided to members of 

the Defense Health Board before the 

meeting that is subject to this notice. 

After reviewing the written comments, 

the Chairperson and the Designated 

Federal Officer may choose to invite the 

submitter of the comments to orally 

present their issue during an open 

portion of this meeting or at a future 

meeting. 

The Designated Federal Officer, in 

consultation with the Defense Health 

Board Chairperson, may, if desired, allot 

a specific amount of time for members 

of the public to present their issues for 

review and discussion by the Defense 

Health Board. 

FOR FURTHER INFORMATION CONTACT: 

Colonel Roger L. Gibson, Executive 

Secretary, Defense Health Board, Five 

Skyline Place, 5111 Leesburg Pike, 

Room 810, Falls Church, Virginia 

22041–3206, (703) 681–3279, Ext 123, 

Fax: (703–681–3321, 

(roger.gibson@ha.ods.mil). Additional 

information, agenda updates, and 

meeting registration are available online 

at the Defense Health Board Web site, 

http://www.ha.osd.mil/dhb. The public 

is encouraged to register for the meeting. 

Written statements may be mailed to the 

above address, e-mailed to 

dhb@ha.osd.mil of faxed to (703) 681–

3321. 

Dated: October 29, 2007. 

L.M. Bynum, 

Liaison Officer, Department of Defense. 

[FR Doc. 07–5455 Filed 11–1–07; 8:45 am] 

BILLING CODE 5501–06–M 


pwalker on PROD1PC71 with NOTICES